Protagonist Therapeutics Director Executes Pre-Arranged Share Sale
Protagonist Therapeutics director William D. Waddill executed a $969,120 sale of 9,000 shares on June 10, 2026, following the exercise of fully vested stock options. The transaction, conducted under a pre-arranged 10b5-1 trading plan, reduces his direct holdings to 7,825 shares. The sale occurs as the stock trades near its 52-week high of $111.45, …